Cell line · CVCL_4Y35
22Rv1 R
Cancer cell line, Homo sapiens. Prostate carcinoma. 5 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Cite this record
ConductScience Library. 22Rv1 R. Cell lines, record CVCL_4Y35. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_4Y35
On this page
Cell line
As Cellosaurus gives it.
- Name
- 22Rv1 R
- Accession
- CVCL_4Y35
- RRID
- RRID:CVCL_4Y35
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- Adult
- Category
- Cancer cell line
- Diseases
- Prostate carcinoma (NCIt C4863)
- Derived from
- Prostate (in situ)
- Parent
- 22Rv1 (CVCL_1045)
- Entry created
- 2015-12-14
- Entry updated
- 2024-12-19
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers5
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Loss of IGF-1R impairs DNA-PKcs recruitment to chromatin leading to defective end-joining. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KBTBD11 loss promotes AKT hyperactivation and therapeutic vulnerability in prostate cancer. | Oncogene | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. | Mol Cancer | 2011 | Cellosaurus cites it | PubMed |
Relatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Parent | 22Rv1 | CVCL_1045 |
Source Cell lines
Cell banks0
None in this release.
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4Y35
GET https://conductscience.org/api/cell-lines/v1/CVCL_4Y35/problems